Clinical Trials Logo

Clinical Trial Summary

40 subjects with a confirmed diagnosis of IBD or >6 months post-RYGB with a diagnosed USD event or kidney stone on imaging within the past three years and 40 healthy controls will be administered a high oxalate diet on Days 0-3 and Days 21-24 with a washout period on Days 4-7 and will be administered 250mg sodium oxalate on Days 8-20, via prepared spinach, from Weil Cornell Medicine's Clinical and Translational Science Center. Subjects will partake in four stool collections, four 24-h urine collections, two blood collections, and four sets of colonic permeability testing.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05124886
Study type Interventional
Source NYU Langone Health
Contact Lama Nazzal, MD
Phone 212-263-2922
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date November 20, 2021
Completion date November 1, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04629170 - Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria Phase 1
Completed NCT03456830 - Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria Phase 3
Recruiting NCT04909723 - Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects Phase 1/Phase 2
Completed NCT03391804 - Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia Phase 2
Completed NCT00588120 - Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria Phase 1
Recruiting NCT03847090 - Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria Phase 3